Everolimus/Exemestane Regimen — drug

Regulatory

Approvals (0)

Each record names the authority, jurisdiction, indication text and status. A drug approved in one jurisdiction for one indication is not 'approved' in general.

Data not yet available

No regulatory approval recorded. Absence here is not evidence of absence: only ingested jurisdictions are covered.

What CancerIndex knows

Curated evidence below
Sources

Derived

Development pipeline

Most advanced stage across all cancers, then per top-level cancer reached through trial conditions or approval indications. Approval in any ingested jurisdiction outranks trial phase; counts are interventional studies.

Data not yet available

No registered interventional trial or approval record places this drug in the pipeline yet.

Curated evidence

Clinical evidence (3)

CIViC items in which this therapy appears, grouped by cancer context, then molecular profile. 50 items per page.

civicCuratedShowing 1–3 of 3 evidence items · levels, directions and significance as curated at the source; each row links to its CIViC record.

Therapy	Cancer	Type	Level	Direction · significance	Rating (1–5)	Status	Evidence	Source
ERBB2 Overexpression + ESR1 Expression + PGR ExpressionPGR ERBB2

Clinical trials

Trials with this intervention (1)

Most recently updated first, 50 per page.

clinicaltrialsPublishedShowing 1–1 of 1 studies · status and phase as posted by the registrant; each row links to the study record.

NCT	Title	Status	Phase	Enrollment (n)	Sponsor	Countries	Last update	Source
NCT02023359	Danish Observational Study of Everolimus Plus Exemestane in Hormone Receptor (HR) Positive, Human Epidermal Growth Factor 2 (HER2) - Metastatic Breast Cancer	completed	—	7	Novartis Healthcare A/SINDUSTRY	1	Dec 29, 2015	clinicaltrials

ESR1 Expression2
Everolimus/Exemestane Regimen	Estrogen Receptor-positive Breast CancerUNRESOLVED	Predictive	B	Does Not Support Sensitivity Response	3	submitted	EID12907 In the same open-label randomized phase II BOLERO-6 trial (NCT01783444; n = 309), everolimus plus exemestane (n = 104) did not support improved PFS versus capecitabine monotherapy (n = 102) in ER+/HER… (full text at CIViC) PMID 29862411 · Jerusalem et al., 2018 · Open in CIViC	civic
〃	Estrogen Receptor-positive Breast CancerUNRESOLVED	Predictive	B	Supports Sensitivity Response	3	submitted	EID12908 In the open-label randomized phase II BOLERO-6 trial (NCT01783444; n = 309) of postmenopausal women with ER+/HER2− advanced breast cancer progressing on nonsteroidal aromatase inhibitors, everolimus p… (full text at CIViC) PMID 29862411 · Jerusalem et al., 2018 · Open in CIViC	civic